Table 3.
Association of Paxillin Expression with Clinicopathological Features of Prostate Cancer.
| Variables | N | Paxillin expression | P-value | |||
|---|---|---|---|---|---|---|
| - | + | ++ | +++ | |||
| Total, n (%) | 386 | 89 | 94 | 102 | 101 | |
| Age (yrs) | ||||||
| <70 | 189(49.0) | 41(46.1) | 50(53.2) | 49(48.0) | 49(48.5) | 0.960 |
| ≧70 | 197(51.0) | 48(53.9) | 44(46.8) | 53(52.0) | 52(51.5) | |
| PSA Level (ng/ml) | ||||||
| <10 | 62(16.1) | 17(19.1) | 25(26.6) | 11(10.8) | 9(8.9) | 0.014 |
| 10-20 | 252(65.3) | 52(58.4) | 56(59.6) | 72(70.6) | 72(71.3) | |
| >20 | 72(18.7) | 20(22.5) | 13(13.8) | 19(18.6) | 20(19.8) | |
| Gleason Score | ||||||
| <7 | 99(25.6) | 48(53.9) | 32(34.0) | 15(14.7) | 4(4.0) | <0.001 |
| 7 | 189(49.0) | 26(29.2) | 43(45.7) | 52(51.0) | 68(67.3) | |
| >7 | 98(25.4) | 15(16.9) | 19(20.2) | 35(34.3) | 29(28.7) | |
| cT stage | ||||||
| T1 | 60(15.5) | 38(42.7) | 11(11.7) | 6(5.9) | 5(5.0) | <0.001 |
| T2 | 259(67.1) | 41(46.1) | 78(83.0) | 80(78.4) | 60(59.4) | |
| T3 | 67(17.4) | 10(11.2) | 5(5.3) | 16(15.7) | 36(35.6) | |
| Lymph node metastasis | ||||||
| Yes | 129(33.4) | 7(7.9) | 24(25.5) | 41(40.2) | 57(56.4) | <0.001 |
| No | 257(66.6) | 82(92.1) | 70(74.5) | 61(59.8) | 44(43.6) | |
| Extracapsular extension | ||||||
| Yes | 67(17.4) | 10(11.2) | 5(5.3) | 16(15.7) | 36(35.6) | <0.001 |
| No | 319(82.6) | 79(88.6) | 89(94.7) | 86(84.3) | 65(64.4) | |
| Seminal vesicle invasion | ||||||
| Yes | 21(5.4) | 0(0.0) | 3(3.2) | 10(9.8) | 8(7.9) | 0.004 |
| No | 365(94.6) | 89(100.0) | 91(96.8) | 92(90.2) | 93(92.1) | |
| Positive surgical margin | ||||||
| Yes | 45(11.7) | 9(10.1) | 4(4.3) | 11(10.8) | 21(20.8) | 0.006 |
| No | 341(88.3) | 80(89.9) | 90(95.7) | 91(89.2) | 80(79.2) | |